|
1
|
Fandi A, Altun M, Azli N, Armand JP and
Cvitkovic E: Nasopharyngeal cancer: Epidemiology, staging, and
treatment. Semin Oncol. 21:382–397. 1994.PubMed/NCBI
|
|
2
|
Henle G and Henle W: Epstein-Barr
virus-specific IgA serum antibodies as an outstanding feature of
nasopharyngeal carcinoma. Int J Cancer. 17:1–7. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pathmanathan R, Prasad U, Sadler R, Flynn
K and Raab-Traub N: Clonal proliferations of cells infected with
Epstein-Barr virus in preinvasive lesions related to nasopharyngeal
carcinoma. New Engl J Med. 333:693–698. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsu MM and Tu SM: Nasopharyngeal carcinoma
in Taiwan. Clinical manifestations and results of therapy. Cancer.
52:362–368. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vokes EE, Liebowitz DN and Weichselbaum
RR: Nasopharyngeal carcinoma. Lancet. 350:1087–1091. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geara FB, Sanguineti G, Tucker SL, et al:
Carcinoma of the nasopharynx treated by radiotherapy alone:
Determinants of distant metastasis and survival. Radiother Oncol.
43:53–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baujat B, Audry H, Bourhis J, et al:
MAC-NPC Collaborative Group: Chemotherapy in locally advanced
nasopharyngeal carcinoma: An individual patient data meta-analysis
of eight randomized trials and 1753 patients. Int J Radiat Oncol
Biol Phys. 64:47–56. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin JC, Jan JS, Hsu CY, et al: Phase III
study of concurrent chemoradiotherapy versus radiotherapy alone for
advanced nasopharyngeal carcinoma: Positive effect on overall and
progression-free survival. J Clin Oncol. 21:631–637. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan AT, Teo PM, Ngan RK, et al:
Concurrent chemotherapy-radiotherapy compared with radiotherapy
alone in locoregionally advanced nasopharyngeal carcinoma:
Progression-free survival analysis of a phase III randomized trial.
J Clin Oncol. 20:2038–2044. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wee J, Tan EH, Tai BC, et al: Randomized
trial of radiotherapy versus concurrent chemoradiotherapy followed
by adjuvant chemotherapyin patients with American Joint Committee
on Cancer/International Union against cancer stage III and IV
nasopharyngeal cancer of the endemic variety. J Clin Oncol.
23:6730–6738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Liu MZ, Liang SB, et al:
Preliminary results of a prospective randomized trial comparing
concurrent chemoradiotherapy plus adjuvant chemotherapy with
radiotherapy alone in patients with locoregionally advanced
nasopharyngeal carcinoma in endemic regions of China. Int J Radiat
Oncol Biol Phys. 71:1356–1364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pfister DG, Ang KK, Brizel DM, et al:
National Comprehensive Cancer Network Head and Neck Cancers,
Version 2.2013 Featured updates on the NCCN guidelines. J Natl
Compr Cancer Netw. 11:917–923. 2013.
|
|
14
|
Al-Sarraf M, LeBlanc M, Giri PG, et al:
Chemoradiotherapy versus radiotherapy in patients with advanced
nasopharyngeal cancer: Phase III randomized Intergroup study 0099.
J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
|
|
15
|
Hui EP, Leung SF, Au JS, et al: Lung
metastasis alone in nasopharyngeal carcinoma: A relatively
favorable prognostic group. A study by the Hong Kong Nasopharyngeal
Carcinoma Study Group. Cancer. 101:300–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee AW, Sze WM, Au JS, et al: Treatment
results for nasopharyngeal carcinoma in the modern era: The Hong
Kong experience. Int J Radiat Oncol. 61:1107–1116. 2005. View Article : Google Scholar
|
|
17
|
Lee N, Xia P, Quivey JM, et al:
Intensity-modulated radiotherapy in the treatment of nasopharyngeal
carcinoma: An update of the UCSF experience. Int J Radiat Oncol
Biol Phys. 53:12–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Langendijk JA, Leemans CR, Buter J,
Berkhof J and Slotman BJ: The additional value of chemotherapy to
radiotherapy in locally advanced nasopharyngeal carcinoma: A
meta-analysis of the published literature. J Clin Oncol.
22:4604–4612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chua DT, Ma J, Sham JS, et al: Long-term
survival after cisplatin-based induction chemotherapy and
radiotherapy for nasopharyngeal carcinoma: A pooled data analysis
of two phase III trials. J Clin Oncol. 23:1118–1124. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hui EP, Ma BB, Leung SF, et al: Randomized
phase II trial of concurrent cisplatinradiotherapy with or without
neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal
carcinoma. J Clin Oncol. 27:242–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
OuYang PY, Xie C, Mao YP, et al:
Significant efficacies of neoadjuvant and adjuvant chemotherapy for
nasopharyngeal carcinoma by meta-analysis of published
literature-based randomized, controlled trials. Ann Oncol.
24:2136–2146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barton-Burke M: Gemcitabine: A
pharmacologic and clinical overview. Cancer Nurs. 22:176–183. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leong SS, Wee J, Tay MH, et al:
Paclitaxel, carboplatin and gemcitabine in metastatic
nasopharyngeal carcinoma: A phase II trial using a triplet
combination. Cancer. 103:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Foo KF, Tan EH, Leong SS, et al:
Gemcitabine in metastatic nasopharyngeal carcinoma of the
undifferentiated type. Ann Oncol. 13:150–156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ngan RK, Yiu HH, Lau WH, et al:
Combination gemcitabine and cisplatin chemotherapy for metastatic
or recurrent nasopharyngeal carcinoma: Report of a phase II study.
Ann Oncol. 13:1252–1258. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang CC, Chang JY, Liu TW, et al: Phase II
study of gemcitabine plus vinorelbine in the treatment of
cisplatin-resistant nasopharyngeal carcinoma. Head Neck. 28:74–80.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurita H, Yamamoto E, Nozaki S, et al:
Multicenter phase I trial of induction chemotherapy with docetaxel
and nedaplatin for oral squamous cell carcinoma. Oral Oncol.
40:1000–1006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng J, Wang G, Yang GY, et al: Induction
chemotherapy with nedaplatin with 5-FU followed by
intensity-modulated radiotherapy concurrent with chemotherapy for
locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol.
40:425–431. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsumoto M, Takeda Y, Maki H, et al:
Preclinical in vivo antitumor efficacy of nedaplatin with
gemcitabine against human lung cancer. Jpn J Cancer Res. 92:51–58.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lim AM, Corry J, Collins M, et al: A phase
II study of induction carboplatin and gemcitabine followed by
chemoradiotherapy for the treatment of locally advanced
nasopharyngeal carcinoma. Oral Oncol. 49:468–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu MF, Liu LZ, He LJ, et al: Sequential
chemoradiotherapy with gemcitabine and cisplatin for locoregionally
advanced nasopharyngeal carcinoma. Int J Cancer. 132:215–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yau TK, Lee AW, Wong DH, et al: Induction
chemotherapy with cisplatin and gemcitabine followed by accelerated
radiotherapy and concurrentcisplatin in patients with stage IV
(A-B) nasopharyngeal carcinoma. Head Neck. 28:880–887. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He X, Ou D, Ying H, et al: Experience with
combination of cisplatin plus gemcitabine chemotherapy and
intensity-modulated radiotherapy for locoregionally advanced
nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 269:1027–1033.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han SH, Yu L, Zhang Z, et al: Evaluation
of induction chemotherapy with vinorelbine plus cisplatin (NP) or
docetaxel plus cisplatin (TP) combined with concurrent
chemoradiotherapy for patients with locally advanced nasopharyngeal
carcinoma. Zhonghua Zhong Liu Za Zhi. 35:623–626. 2013.(In
Chinese). PubMed/NCBI
|
|
35
|
Zhong YH, Dai J, Wang XY, et al: Phase II
trial of neoadjuvant docetaxel and cisplatin followed by
intensity-modulated radiotherapy with concurrent cisplatin in
locally advanced nasopharyngeal carcinoma. Cancer Chemother
Pharmacol. 71:1577–1583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ekenel M, Keskin S, Basaran M, et al:
Induction chemotherapy with docetaxel and cisplatin is highly
effective for locally advanced nasopharyngeal carcinoma. Oral
Oncol. 47:660–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du C, Ying H, Zhou J, Hu C and Zhang Y:
Experience with combination of docetaxel, cisplatin plus
5-fluorouracil chemotherapy and intensity-modulated radiotherapy
for locoregionally advanced nasopharyngeal carcinoma. Int J Clin
Oncol. 18:464–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kong L, Hu C, Niu X, et al: Neoadjuvant
chemotherapy followed by concurrent chemoradiation for
locoregionally advanced nasopharyngeal carcinoma: Interim results
from 2 prospective phase 2 clinical trials. Cancer. 119:4111–4118.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen L, Mao YP, Xie FY, et al: The seventh
edition of the UICC/AJCC staging system for nasopharyngeal
carcinoma is prognostically useful for patients treated with
intensity-modulated radiotherapy from an endemic area in China.
Radiother Oncol. 104:331–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984.PubMed/NCBI
|
|
41
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: Revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu YJ, Zhu GP and Guan XY: Comparison of
the NCI-CTCAE version 4.0 and version 3.0 in assessing
chemoradiation-induced oral mucositis for locally advanced
nasopharyngeal carcinoma. Oral Oncol. 48:554–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thompson L: World Health Organization
classification of tumours: Pathology and genetics of head and neck
tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI
|
